HOME >> MEDICINE >> NEWS
Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years

THOUSAND OAKS, Calif., November 13, 2006 -- Amgen (NASDAQ: AMGN), today announced that data from an ongoing open-label, multinational, phase 4 extension study showed that patients with ankylosing spondylitis (AS) who received treatment with Enbrel? (etanercept) experienced sustained improvement in signs and symptoms, spinal mobility and physical function over 148 to 160 weeks of therapy. These results are consistent with an ENBREL phase 3 clinical trial at 24 weeks. The 160-week results will be presented at the American College of Rheumatology (ACR) Scientific Meeting in Washington, D.C.

"These data demonstrate that ENBREL can provide substantial long-term improvement in AS symptoms such as total back pain and spinal mobility," said Joachim Sieper, M.D., professor of rheumatology, Charite University in Berlin, Germany. "Because AS is a chronic inflammatory disease that requires ongoing management, it is important to offer patients a treatment option that is effective, has an established safety profile, and can be used over the long-term."

Data presented at ACR showed that 59 patients who received open-label ENBREL treatment for up to 160 weeks experienced sustained clinical improvements. Overall, 78 percent of patients (n=46) continuing treatment with ENBREL achieved a 20 percent improvement in the Assessment on Ankylosing Spondylitis Response Criteria (ASAS 20) after 160 weeks of treatment. ASAS is a composite measure of improvement in AS symptoms that include total back pain, patient assessment of disease activity, inflammation and physical function. Thirty-one percent of patients (n= 18) achieved partial remission at week 160. Partial remission, as defined by ASAS, is a low disease activity level (score < 20 units out of 100 in each of the four ASAS criteria).

Additional ENBREL data presented at ACR from this phase 4 extension study show that improvement in spinal mobility was also sustained through 148 to 160 weeks of
'"/>

Contact: Sonia Fiorenza
805-447-1604
Porter Novelli
13-Nov-2006


Page: 1 2 3

Related medicine news :

1. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
2. Sports concussion research using fMRI provides insight for safe return-to-play decisions
3. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
4. Daytrana provides significant effectiveness in both boys and girls with ADHD
5. New book provides unprecedented look at role of religion over a lifetime
6. New edition of medical reference book provides the latest in hematology
7. Lung cancer screening regimen provides opportunity for cure
8. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
9. IceSAR campaign provides glimpse of future Sentinel-1 images over ice
10. Darunavir with FUZEON provides HIV patients a better chance to reach undetectable viral load
11. Optical technique provides improved virtual biopsies of internal surfaces

Post Your Comments:
(Date:8/29/2014)... VA (PRWEB) August 29, 2014 ... Food and Drug Administration (FDA), Center for Food ... single-award, indefinite delivery, indefinite quantity (IDIQ) contract and ... and Maintenance” and “Development, Modernization and Enhancement (DME) ... and CRGT. , Overarching contract objectives include:, ...
(Date:8/29/2014)... August 29, 2014 Two Kelowna dentists ... nearly $22,000 to ship a container filled with classroom materials, ... village in Haiti. , “I don’t ... children,” says Dr. Debra Matson-Visscher. She and her husband, Dr. ... have been a big part of New Reality International’s (NRI) ...
(Date:8/28/2014)... Arizona (PRWEB) August 28, 2014 When ... and long-time friend of Mark Brnovich, was asked ... the Republican nomination for the Attorney General seat in ... He quickly gathered the support of Cardinal Hall of ... Arizona Cardinals Derek Kennard and Mark Walczak. Green, Kennard ...
(Date:8/28/2014)... Starting on Monday, the Mesothelioma Applied ... in Bitcoin, in addition to all the traditional ways ... at http://www.curemeso.org/bitcoin . , “As more and ... payment, we decided it was important for us to ... Melinda Kotzian. , Bitcoin is an online-only, internet ...
(Date:8/28/2014)... evidence for these particular arguments against the policy, put ... Australia was the first country in the world to ... New Zealand, Ireland, and the UK are currently considering ... if the policy would deter people from buying their ... the availability of cheap products sourced from Asia, and ...
Breaking Medicine News(10 mins):Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 2Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 3Health News:From Canada to Haiti: Kelowna Dentists Raise Funds to Ship Supplies to Self-Sustaining Village for Orphans 2Health News:From Canada to Haiti: Kelowna Dentists Raise Funds to Ship Supplies to Self-Sustaining Village for Orphans 3Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Cancer Research Funding Organization Now Accepts Bitcoin Donations 2Health News:Plain cigarette packs don't hurt small retailers or boost trade in illicit tobacco 2
(Date:8/28/2014)... CASTLE ROCK, Colo. , Aug. 28, 2014 /PRNewswire/ ... diagnostic company focused on obtaining FDA clearance for ... a rapid blood test for aiding in identifying children, ... who are at low risk for appendicitis, today announced ... Rodman & Renshaw 16 th Annual Global Investment ...
(Date:8/28/2014)... DIEGO , Aug. 28, 2014 Telik, ... development company that merged with MabVax Therapeutics, Inc. ... made significant progress related to the development of ... antibody was recovered using the Company,s internally developed ... the potential for multiple antibody based therapeutic and ...
(Date:8/28/2014)... DUBLIN, Ohio , Aug. 28, 2014 /PRNewswire/ ... rising competition in generics are adding pressure to ... internal resources. Company resources continue to shrink and ... complex. This has led companies to look for ... to commercialization and for keeping approved products on ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 44 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4
Cached News: